These results and the observation that loss of even a single allele of Mcl-1 efficiently kills malignant Eμ-Myc lymphoma cells41 provide further impetus to develop MCL-1 specific inhibitors (e.g. BH3 mimetics) for cancer therapy.50, 51. The gene discussed is MYC; the disease is lymphoma.